Fibrate-modulated Expression of Fibrinogen, Plasminogen Activator Inhibitor-1 and Apolipoprotein A-I in Cultured Cynomolgus Monkey Hepatocytes

Summary

Fibrates are used to lower plasma triglycerides and cholesterol levels in hyperlipidemic patients. In addition, fibrates have been found to alter the plasma concentrations of fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and apolipoprotein A-I (apo A-I). We have investigated the in vitro effects of fibrates on fibrinogen, PAI-1 and apo A-I synthesis and the underlying regulatory mechanisms in primary monkey hepatocytes.

We show that fibrates time- and dose-dependently increase fibrinogen and apo A-I expression and decrease PAI-1 expression in cultured cynomolgus monkey hepatocytes, the effects demonstrating different potency for different fibrates. After three consecutive periods of 24 h the most effective fibrate, ciprofibrate (at 1 mmol/l), increased fibrinogen and apo A-I synthesis to 356% and 322% of control levels, respectively. Maximum inhibition of PAI-1 synthesis was about 50% of control levels and was reached by 1 mmol/l gemfibrozil or ciprofibrate after 48 h. A ligand for the retinoid-X-receptor (RXR), 9-cis retinoic acid, and specific activators of the peroxisome proliferator-activated receptor-α (PPARα), Wy14,643 and ETYA, influenced fibrinogen, PAI-1 and apo A-I expression in a similar fashion, suggesting a role for the PPARα/RXRα heterodimer in the regulation of these genes. When comparing the effects of the various compounds on PPARα trans-activation activity as determined in a PPARα-sensitive reporter gene system and the ability of the compounds to affect fibrinogen, PAI-1 and apo A-I antigen production, a good correlation (r = 0.80; p <0.01) between PPARα transactivation and fibrinogen expression was found. Apo A-I expression correlated only weakly with PPARα transactivation activity (r = 0.47; p = 0.24), whereas such a correlation was absent for PAI-1 (r = 0.03; p = 0.95). These results strongly suggest an involvement of PPARα in the regulation of fibrinogen gene expression.

• References

• 1 Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994; 111: 161-74.
• 2 Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. N Engl J Med 1995; 332: 512-21.
• 3 Tikkanen MJ. Fibric acid derivatives. Curr Opin Lipidol 1990; 1: 262-9.
• 4 Schoonjans K, Staels B, Auwerx J. Role of peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 27: 907-25.
• 5 Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol 1996; 12: 335-63.
• 6 Peters JM, Hennuyer N, Staels B, Fruchart J-C, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J Biol Chem 1997; 272: 27307-12.
• 7 Forman BM, Chen J, Evans M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 1997; 94: 4312-7.
• 8 Arts J, Kockx M, Princen HMG, Kooistra T. Studies on the mechanism of fibrate-inhibited expression of plasminogen activator inhibitor-1 in cultured hepatocytes from cynomolgus monkey. Arterioscler Thromb Vasc Biol 1997; 17: 26-32.
• 9 Princen HMG, Huijsmans CMG, Kuipers F, Vonk RJ, Kempen HJM. Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7α-hydroxylase. J Clin Invest 1986; 78: 1064-71.
• 10 Kooistra T, Bosma PJ, Töns HAM, Van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-8.
• 11 Kaptein A, De Wit ECM, Princen HMG. Retinoids stimulate apo A-I synthesis by induction of gene transcription in primary hepatocyte cultures from cynomolgus monkey (macaca fascicularis) . Arterioscler Thromb 1993; 13: 1505-14.
• 12 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
• 13 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed., Cold. Spring. Harbor Laboratory Cold Spring Harbor, NY; 1989
• 14 Kessling AM, Horsthemke B, Humphries SE. A study of DNA polymorphisms around the human apolipoprotein A-I gene in hyperlipidaemic and normal individuals. Clin Genetics 1985; 28: 296-306.
• 15 Van den Berg AP, Sprengers ED, Jaye M, Burgess W, Maciag T, Van Hinsbergh VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost 1988; 13: 1431-42.
• 16 Wilson GN, Hollar BA, Waterson JR, Schmickel RD. Molecular analysis of cloned human 18S ribosomal DNA segments. Proc Natl Acad Sci USA 1978; 75: 5367-71.
• 17 Kaptein A, Roodenburg L, Princen HMG. Butyrate stimulates the secretion of apolipoprotein (apo) A-I and apo B100 by the human hepatoma cell line Hep G2: induction of apo A-I mRNA with no change in apo B100 mRNA. Biochem J 1991; 278: 557-64.
• 18 Hoegee-De Nobel E, Voskuilen M, Briët E, Brommer EJP, Nieuwenhuizen W. A monoclonal antibody-based quantitative enzyme immunoassay for the determination of plasma fibrinogen concentrations. Thromb Haemost 1988; 60: 415-8.
• 19 Ernst E. Lowering the plasma fibrinogen concentration with drugs. Clin Pharmacol 1992; 11: 968-71.
• 20 Thompson SG, Kienast J, Pyke SDM, Haverkate F, Van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995; 332: 635-41.
• 21 Kiserud CE, Kierulf P, Hostmark AT. Effects of various fatty acids alone or combined with vitamin E on cell growth and fibrinogen concentration in the medium of HepG₂ cells. Thromb Res 1995; 80: 75-83.
• 22 Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 1997; 94: 4318-23.
• 23 Pickart L. Free fatty acidemia as an inducer of systemic hyperfibrinogenemia and fibrinolytic inhibition. Inflammation 1981; 5: 61-70.
• 24 Handley DA, Hughes TE. Pharmacological approaches and strategies for therapeutic modulation of fibrinogen. Thromb Res 1997; 87: 1-36.
• 25 Pickart L. Suppression of acute-phase synthesis of fibrinogen by a hypolipidemic drug (clofibrate). Int J Tissue React 1981; 3: 65-72.
• 26 Kockx M, De Maat MPM, Knipscheer HC, Kastelein JJP, Kluft C, Princen HMG, Kooistra T. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients. Thromb Haemost 1997; 78: 1167-72.
• 27 Branchi A, Rovelline A, Sommariva D, Gugliandolo AG, Faoli A. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen levels in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241-3.
• 28 Simpson IA, Lorimer R, Walker ID, Davidson JF. Effect of ciprofibrate on platelet aggregation and fibrinolysis in patients with hypercholesterolaemia. Thromb Haemost 1985; 54: 442-4.
• 29 Nicodeme E, Nicaud M, Issandou M. Retinoids stimulate fibrinogen production both in vitro (hepatocytes) and in vivo. Arterioscler Thromb Vasc Biol 1995; 15: 1660-7.
• 30 Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, Fruchart J-C, Rubin E, Denèfle P, Staels B, Branellec D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 97: 2408-16.
• 31 Murray RW, Marotti KR. Nucleotide sequence of the cynomolgus monkey apolipoprotein A-I gene and corresponding flanking regions. Biochim Biophys Acta 1992; 1131: 207-10.
• 32 Fuji S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Heamost 1993; 70: 642-7.
• 33 Nordt TK, Kornas K, Peter K, Fujii S, Sobel BE, Kübler W, Bode C. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Circulation 1997; 95: 677-83.
• 34 Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1998; 18: 20-6.